179 related articles for article (PubMed ID: 19942619)
1. The iron chelator deferasirox enhances liposomal amphotericin B efficacy in treating murine invasive pulmonary aspergillosis.
Ibrahim AS; Gebremariam T; French SW; Edwards JE; Spellberg B
J Antimicrob Chemother; 2010 Feb; 65(2):289-92. PubMed ID: 19942619
[TBL] [Abstract][Full Text] [Related]
2. Comparative pharmacodynamics of posaconazole in neutropenic murine models of invasive pulmonary aspergillosis and mucormycosis.
Lewis RE; Albert ND; Kontoyiannis DP
Antimicrob Agents Chemother; 2014 Nov; 58(11):6767-72. PubMed ID: 25182639
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic and toxicologic studies in a murine model of invasive pulmonary aspergillosis.
Clemons KV; Schwartz JA; Stevens DA
Med Mycol; 2011 Nov; 49(8):834-47. PubMed ID: 21539507
[TBL] [Abstract][Full Text] [Related]
4. Assessment of efficacy of antifungals against Aspergillus fumigatus: value of real-time bioluminescence imaging.
Galiger C; Brock M; Jouvion G; Savers A; Parlato M; Ibrahim-Granet O
Antimicrob Agents Chemother; 2013 Jul; 57(7):3046-59. PubMed ID: 23587947
[TBL] [Abstract][Full Text] [Related]
5. The iron chelator deferasirox protects mice from mucormycosis through iron starvation.
Ibrahim AS; Gebermariam T; Fu Y; Lin L; Husseiny MI; French SW; Schwartz J; Skory CD; Edwards JE; Spellberg BJ
J Clin Invest; 2007 Sep; 117(9):2649-57. PubMed ID: 17786247
[TBL] [Abstract][Full Text] [Related]
6. Combination therapy with micafungin and amphotericin B for invasive pulmonary aspergillosis in an immunocompromised mouse model.
Nagasaki Y; Eriguchi Y; Uchida Y; Miyake N; Maehara Y; Kadowaki M; Harada M; Akashi K; Shimono N
J Antimicrob Chemother; 2009 Aug; 64(2):379-82. PubMed ID: 19465436
[TBL] [Abstract][Full Text] [Related]
7. Combination therapy of murine mucormycosis or aspergillosis with iron chelation, polyenes, and echinocandins.
Ibrahim AS; Gebremariam T; Luo G; Fu Y; French SW; Edwards JE; Spellberg B
Antimicrob Agents Chemother; 2011 Apr; 55(4):1768-70. PubMed ID: 21263057
[TBL] [Abstract][Full Text] [Related]
8. Delay of antifungal therapy influences the outcome of invasive aspergillosis in experimental models of infection.
Barchiesi F; Santinelli A; Biscotti T; Greganti G; Giannini D; Manso E
J Antimicrob Chemother; 2016 Aug; 71(8):2230-3. PubMed ID: 27231274
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of liposomal amphotericin B for prophylaxis of acute or reactivation models of invasive pulmonary aspergillosis.
Leleu C; Menotti J; Meneceur P; Choukri F; Sulahian A; Garin YJ; Derouin F
Mycoses; 2013 May; 56(3):241-9. PubMed ID: 22998025
[TBL] [Abstract][Full Text] [Related]
10. Pulmonary aspergillosis in mice: treatment with a new triazole SCH39304.
Defaveri J; Salazar MH; Rinaldi MG; Graybill JR
Am Rev Respir Dis; 1990 Sep; 142(3):512-5. PubMed ID: 2202244
[TBL] [Abstract][Full Text] [Related]
11. Application of a low molecular weight antifungal protein from Penicillium chrysogenum (PAF) to treat pulmonary aspergillosis in mice.
Palicz Z; Gáll T; Leiter É; Kollár S; Kovács I; Miszti-Blasius K; Pócsi I; Csernoch L; Szentesi P
Emerg Microbes Infect; 2016 Nov; 5(11):e114. PubMed ID: 27826143
[TBL] [Abstract][Full Text] [Related]
12. Liposomal amphotericin B and echinocandins as monotherapy or sequential or concomitant therapy in murine disseminated and pulmonary Aspergillus fumigatus infections.
Olson JA; George A; Constable D; Smith P; Proffitt RT; Adler-Moore JP
Antimicrob Agents Chemother; 2010 Sep; 54(9):3884-94. PubMed ID: 20606065
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of voriconazole against invasive pulmonary aspergillosis in a guinea-pig model.
Chandrasekar PH; Cutright J; Manavathu E
J Antimicrob Chemother; 2000 May; 45(5):673-6. PubMed ID: 10797091
[TBL] [Abstract][Full Text] [Related]
14. Posaconazole pharmacodynamic target determination against wild-type and Cyp51 mutant isolates of Aspergillus fumigatus in an in vivo model of invasive pulmonary aspergillosis.
Lepak AJ; Marchillo K; Vanhecker J; Andes DR
Antimicrob Agents Chemother; 2013 Jan; 57(1):579-85. PubMed ID: 23147740
[TBL] [Abstract][Full Text] [Related]
15. The Deferasirox-AmBisome Therapy for Mucormycosis (DEFEAT Mucor) study: a randomized, double-blinded, placebo-controlled trial.
Spellberg B; Ibrahim AS; Chin-Hong PV; Kontoyiannis DP; Morris MI; Perfect JR; Fredricks D; Brass EP
J Antimicrob Chemother; 2012 Mar; 67(3):715-22. PubMed ID: 21937481
[TBL] [Abstract][Full Text] [Related]
16. Combination therapy of advanced invasive pulmonary aspergillosis in transiently neutropenic rats using human pharmacokinetic equivalent doses of voriconazole and anidulafungin.
van de Sande WW; Mathot RA; ten Kate MT; van Vianen W; Tavakol M; Rijnders BJ; Bakker-Woudenberg IA
Antimicrob Agents Chemother; 2009 May; 53(5):2005-13. PubMed ID: 19237647
[TBL] [Abstract][Full Text] [Related]
17. Synergistic interaction of terbinafine with triazoles or amphotericin B against Aspergillus species.
Ryder NS; Leitner I
Med Mycol; 2001 Feb; 39(1):91-5. PubMed ID: 11270414
[TBL] [Abstract][Full Text] [Related]
18. Proangiogenic growth factors potentiate in situ angiogenesis and enhance antifungal drug activity in murine invasive aspergillosis.
Ben-Ami R; Albert ND; Lewis RE; Kontoyiannis DP
J Infect Dis; 2013 Apr; 207(7):1066-74. PubMed ID: 23303813
[TBL] [Abstract][Full Text] [Related]
19. Combination therapy with iron chelation and vancomycin in treating murine staphylococcemia.
Luo G; Spellberg B; Gebremariam T; Lee H; Xiong YQ; French SW; Bayer A; Ibrahim AS
Eur J Clin Microbiol Infect Dis; 2014 May; 33(5):845-51. PubMed ID: 24292099
[TBL] [Abstract][Full Text] [Related]
20. Managing invasive aspergillosis in haematological patients in the era of resistance polymerase chain reaction and increasing triazole resistance: A modelling study of different strategies.
van de Peppel RJ; van der Beek MT; Visser LG; de Boer MGJ; Wallinga J
Int J Antimicrob Agents; 2019 Mar; 53(3):284-293. PubMed ID: 30395989
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
